146 results
Search Results
2. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats
3. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
4. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
5. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration
6. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
7. Novel electrophilic synthesis of 6-[18F]fluorodopamine and comprehensive biological evaluation
8. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
9. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats
10. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C
11. Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone)
12. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
13. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects
14. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide
15. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
16. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
17. Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): Optimization of the duration of UN dosing
18. [18F]FETO: metabolic considerations
19. Pharmacokinetic Differences between Pantoprazole Enantiomers in Rats
20. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent
21. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents
22. Comparison of the Pharmacokinetics of Oxycodone and Noroxycodone in Male Dark Agouti and Sprague–Dawley Rats: Influence of Streptozotocin-Induced Diabetes
23. Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil
24. Metabolic and pharmacokinetic evaluation of a Novel 3-hydroxypyridinone iron chelator, CP502, in the rat
25. The interaction of the diltiazem with oral and intravenous cyclosporine in rats
26. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog
27. Serotonin neurotoxins — past and present
28. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat
29. The in vivo metabolism of tibolone in animal species
30. Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs
31. Evaluation of the absorption, excretion, and metabolism of the antihypertensive agent RWJ-26899 in male and female CR wistar rats and beagle dogs
32. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma
33. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion
34. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients
35. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine
36. Acetaminophen presystemic biotransformation vs bioavailability in therapeutical dosage range
37. Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs
38. Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration
39. Pharmacokinetics of [14C]-labelled losigamone and enantiomers after oral administration to healthy subjects
40. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I
41. Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers
42. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients
43. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration
44. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys
45. Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses
46. Theophylline pharmacokinetics and metabolism in rabbits following single and repeated administration ofCapsicum fruit
47. Effects of altitude (4300 M) on the pharmacokinetics of caffeine and cardio-green in humans
48. Pharmacokinetics and metabolism of diltiazem in rats following a single intra-arterial or single oral dose
49. Are we doing too many animal biodisposition investigations before Phase I studies in man?: A re-evaluation of the timing and extent of ADME studies
50. Urinary excretion and metabolism of orally administered mefenorex
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.